| Symbol | HROW |
|---|---|
| Name | HARROW, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1A BURTON HILLS BLVD.,SUITE 200, NASHVILLE, Tennessee, 37215, United States |
| Telephone | +1 615 - 733-4730 |
| Fax | — |
| — | |
| Website | https://www.harrow.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001360214 |
| Description | Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits. Additional info from NASDAQ: Additional info from NASDAQ: |
Director BAUM MARK L 🟢 acquired 10.0K shares of HARROW, INC. (HROW) at $30.20 Transaction Date: May 14, 2026 | Filing ID: 023321
Read moreBOLL ANDREW R. 🟢 acquired 3.5K shares of HARROW, INC. (HROW) at $29.90 Transaction Date: May 14, 2026 | Filing ID: 023319
Read moreNew Form SCHEDULE 13G/A - HARROW, INC. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0001493152-26-022235 <b>Size:</b> 23 KB
Read moreNew Form DEFA14A - HARROW, INC. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001493152-26-018914 <b>Size:</b> 941 KB
Read moreNew Form DEF 14A - HARROW, INC. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001493152-26-018912 <b>Size:</b> 9 MB
Read moreNew Form SCHEDULE 13G/A - HARROW, INC. <b>Filed:</b> 2026-03-27 <b>AccNo:</b> 0000102909-26-001499 <b>Size:</b> 7 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07224529 | Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysf… | Phase4 | Meibomian Gland Dysfunction (MGD) | Not_Yet_Recruiting | 2026-05-01 | 2027-02-01 | ClinicalTrials.gov |
| NCT07368595 | Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With… | Phase4 | Dry Eye Disease (DED) | Not_Yet_Recruiting | 2026-04-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT07566975 | Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of … | — | Dry Eye | Recruiting | 2026-03-31 | 2026-11-30 | ClinicalTrials.gov |
| NCT07456826 | Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3… | Phase4 | Diabetic Macular Edema (DME) | Enrolling_By_Invitation | 2026-03-31 | 2026-08-01 | ClinicalTrials.gov |
| NCT05934253 | The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericid… | Phase4 | Antiseptic | Completed | 2023-07-15 | 2024-02-15 | ClinicalTrials.gov |
| NCT07588074 | Tolerability Comparison of Flarex to Lotemax SM | Phase4 | Ocular Inflammation | Completed | 2021-05-01 | 2021-06-30 | ClinicalTrials.gov |
| NCT02372552 | Microwave Coagulation Using CROMA Electrosurgical System | Na | Polyp of Large Intestine | Completed | 2015-08-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT00157066 | Effects of Vitamin D Supplementation on Antimycobacterial Immunity | Na | Tuberculosis | Completed | 2002-12-01 | 2006-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Loteprednol Etabonate Ophthalmic Gel 0.38% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Fluorometholone Acetate Ophthalmic Suspension 0.1% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Loteprednol Etabonate Ophthalmic Gel 0.38% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Fluorometholone Acetate Ophthalmic Suspension 0.1% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Loteprednol Etabonate Ophthalmic Gel 0.38% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Fluorometholone Acetate Ophthalmic Suspension 0.1% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Loteprednol Etabonate Ophthalmic Gel 0.38% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Fluorometholone Acetate Ophthalmic Suspension 0.1% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Loteprednol Etabonate Ophthalmic Gel 0.38% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Fluorometholone Acetate Ophthalmic Suspension 0.1% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Loteprednol Etabonate Ophthalmic Gel 0.38% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Fluorometholone Acetate Ophthalmic Suspension 0.1% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Loteprednol Etabonate Ophthalmic Gel 0.38% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Fluorometholone Acetate Ophthalmic Suspension 0.1% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Loteprednol Etabonate Ophthalmic Gel 0.38% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Fluorometholone Acetate Ophthalmic Suspension 0.1% | Other | Phase PHASE4 | Ocular Inflammation | COMPLETED | NCT07588074 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Cyclosporine ophthalmic solution 0.1% | Other | Preclinical | Dry Eye | RECRUITING | NCT07566975 |
| Ergocalciferol | Other | Approved | Tuberculosis | COMPLETED | NCT00157066 |
| Ergocalciferol | Other | Approved | Tuberculosis | COMPLETED | NCT00157066 |
| CROMA | Other | Approved | Polyp of Large Intestine | COMPLETED | NCT02372552 |
| Chloroprocaine ophthalmic gel 3% | Other | Phase PHASE4 | Antiseptic | COMPLETED | NCT05934253 |
| Cyclosporine emulsion | Other | Phase PHASE4 | Dry Eye Disease (DED) | NOT_YET_RECRUITING | NCT07368595 |
| Vevye® | Other | Phase PHASE4 | Dry Eye Disease (DED) | NOT_YET_RECRUITING | NCT07368595 |
| Lidocaine Hydrochloride Injection 2% | Other | Phase PHASE4 | Diabetic Macular Edema (DME) | ENROLLING_BY_INVITATION | NCT07456826 |
| Proparacaine Hydrochloride Ophthalmic Solution 0.5% | Other | Phase PHASE4 | Diabetic Macular Edema (DME) | ENROLLING_BY_INVITATION | NCT07456826 |
| Sham Subconjunctival Injection | Other | Phase PHASE4 | Diabetic Macular Edema (DME) | ENROLLING_BY_INVITATION | NCT07456826 |
| Chloroprocaine Ophthalmic Gel 3% (IHEEZO) | Other | Phase PHASE4 | Diabetic Macular Edema (DME) | ENROLLING_BY_INVITATION | NCT07456826 |
| CROMA | DEVICE | Approved | Polyp of Large Intestine | COMPLETED | NCT02372552 |
| Lidocaine Hydrochloride Injection 2% | DRUG | Phase PHASE4 | Diabetic Macular Edema (DME) | RECRUITING | NCT07456826 |
| Proparacaine Hydrochloride Ophthalmic Solution 0.5% | DRUG | Phase PHASE4 | Diabetic Macular Edema (DME) | RECRUITING | NCT07456826 |
| Sham Subconjunctival Injection | PROCEDURE | Phase PHASE4 | Diabetic Macular Edema (DME) | RECRUITING | NCT07456826 |
| Chloroprocaine Ophthalmic Gel 3% (IHEEZO) | DRUG | Phase PHASE4 | Diabetic Macular Edema (DME) | RECRUITING | NCT07456826 |
| Cyclosporine emulsion | DRUG | Phase PHASE4 | Dry Eye Disease (DED) | NOT_YET_RECRUITING | NCT07368595 |
| Vevye® | DRUG | Phase PHASE4 | Dry Eye Disease (DED) | NOT_YET_RECRUITING | NCT07368595 |
| Vevye(Cyclosporine 0.1% Ophthalmic Solution) | DRUG | Phase PHASE4 | Meibomian Gland Dysfunction (MGD) | NOT_YET_RECRUITING | NCT07224529 |
| Chloroprocaine ophthalmic gel 3% | DRUG | Phase PHASE4 | Antiseptic | COMPLETED | NCT05934253 |